Home › Research › Tau biomarkers
Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer's disease using the Lumipulse platform
Valera-Barrero A, Martínez-Dubarbie F, Guerra A, López-García S, Lage C, Rivera-Sánchez M, Pozueta-Cantudo A, García-Martínez M et al.. Alzheimer's research & therapy, 2026-03-18
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
BACKGROUND: Plasma glial fibrillary acidic protein (GFAP) has emerged as a promising biomarker of astrocytic reactivity in preclinical Alzheimer´s Disease (AD). However, most evidence to date comes from ultrasensitive research assays, with limited data from automated clinical platforms. We aimed to evaluate the diagnostic performance of plasma GFAP in cognitively unimpaired (CU) individuals using the fully automated Lumipulse platform, and to assess its concordance with a highly sensitive research-based immunoassay, Single Molecule Array (SIMOA).
What this study adds
Evidence grade: Low
The record lists 143 participants. This study evaluated how well plasma GFAP measured on the automated Lumipulse platform performs in cognitively unimpaired individuals, and how it agrees with the SIMOA research assay. It is a diagnostic performance study, not a treatment, cure or prevention study.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Valera-Barrero, A., Martínez-Dubarbie, F., Guerra, A., López-García, S., Lage, C., Rivera-Sánchez, M., et al. (2026). Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer's disease using the Lumipulse platform. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-026-02012-9
Vancouver
Valera-Barrero A, Martínez-Dubarbie F, Guerra A, López-García S, Lage C, Rivera-Sánchez M, et al. Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer's disease using the Lumipulse platform. Alzheimer's research & therapy. 2026. doi:10.1186/s13195-026-02012-9. PMID: 41845424.
BibTeX
@article{valerabarrero2026-41845424,
author = {Valera-Barrero, A. and Martínez-Dubarbie, F. and Guerra, A. and López-García, S. and Lage, C. and Rivera-Sánchez, M. and Pozueta-Cantudo, A. and García-Martínez, M. and others},
title = {{Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer's disease using the Lumipulse platform}},
journal = {Alzheimer's research \& therapy},
year = {2026},
doi = {10.1186/s13195-026-02012-9},
pmid = {41845424},
url = {https://doi.org/10.1186/s13195-026-02012-9}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- However, most evidence to date comes from ultrasensitive research assays, with limited data from automated clinical platforms.
- We aimed to evaluate the diagnostic performance of plasma GFAP in cognitively unimpaired (CU) individuals using the fully automated Lumipulse platform, and to assess its concordance with a highly sensitive research-based immunoassay, Single Molecule Array (SIMOA).
- METHODS: Plasma GFAP, and cerebrospinal fluid (CSF) amyloid-β (Aβ)42/40, phosphorylated tau (p-tau) 181, total tau (t-tau), and neurofilament light chain (NfL) were analyzed in 204 CU participants using the Lumipulse G600II platform.
- In a subset of 143 individuals, it was also measured with SIMOA.
Why it matters
This study evaluated how well plasma GFAP measured on the automated Lumipulse platform performs in cognitively unimpaired individuals, and how it agrees with the SIMOA research assay. It is a diagnostic performance study, not a treatment, cure or prevention study.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants143
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 143 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Marta Fernández‐Matarrubia: h-index 18 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 16 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41845424) |
| Free to read | 2 / 2 | Free to read |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-026-02012-9
- PubMed: 41845424
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.